Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2929 - 2936 of 12086 results

Energy & Sustainability Washington Updates - September 2021
September 14, 2021| News

Webinar Recording - Delta's Impact on Return to Office Plans
September 14, 2021| Blog| Viewpoint

Fifth Circuit FRAND Ruling Could Attract SEP Owners Back to US Courts
September 13, 2021| News

Pricing Overseas Carbon: The Rise of Border Adjustment Mechanisms on Both Sides of the Pond
September 10, 2021| Blog| Viewpoint

Biden Administration’s Drug Pricing Plan Calls for Bold Action by Congress
September 10, 2021| Blog| Viewpoint

Retirement Committee Field Guide: 401(k) Plans from the Platform Provider’s Perspective
September 10, 2021| Podcast| Viewpoint

Biden Administration Unveils Sweeping Workplace Vaccination Plan
September 10, 2021| Blog| Viewpoint

Form I-9 Requirements Flexibility Extended until December 31, 2021
September 9, 2021| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
